Vascular endothelial growth factor released from lenvatinib‐resistant hepatocellular carcinoma promotes malignant behavior and drug resistance through tumor‐associated macrophages

Documenti analoghi

• Mechanism of Lenvatinib Resistance via Exosomal miRNA ‐132/Nrf2 Axis in Hepatocellular Carcinoma
  di: Chie Takasu, et al.
  Pubblicazione: (2025)
• Correction to “Therapeutic efficacy of lenvatinib as third‐line treatment after regorafenib for unresectable hepatocellular carcinoma progression”
  Pubblicazione: (2025)
• Efficacy and safety of lenvatinib‐transcatheter arterial chemoembolization sequential therapy for hepatocellular carcinoma within the up‐to‐seven criteria
  di: Shigeo Shimose, et al.
  Pubblicazione: (2025)
• Comparative analysis of sorafenib and lenvatinib on HepG2 cells and human umbilical vein endothelial cells: Involvement of transforming growth factor‐β signaling in their molecular effects
  di: Ting Wang, et al.
  Pubblicazione: (2024)
• Hepatic arterial infusion chemotherapy combined with lenvatinib and PD‐1 inhibitors versus lenvatinib and PD‐1 inhibitors for HCC refractory to TACE
  di: Lingfeng Diao, et al.
  Pubblicazione: (2024)